Andrew Blumenfeld M.D
He is Board-certified in Neurology by the American Board of Psychiatry and Neurology and is also certified in Headache Medicine.
Dr Blumenfeld is a member and fellow of both the American Academy of Neurology and the American Headache Society. He is the founding chair of the American Headache Society section on Interventional Procedures for Headache. He has published widely and has over 100 publications.
One of his manuscripts was voted the top publication in the Headache journal.
His research interests have focused on the use of Botox for migraine. He helped to develop the injection protocol used in the pivotal migraine trials. He teaches other providers on this procedure nationally and internationally.
He has been an active researcher in headache with 26 issued patents for various treatments.
He consults with numerous pharmaceutical companies involved with medications related to headache disorders, and more details can be found through The Sunshine Act.
Board Certification
Medical Education
First class pass and distinction in Mathematics, 1975
University of the Witwatersrand Faculty of Medicine, Johannesburg, South Africa
Bachelor of Medicine and Surgery (MD equivalent), 1976-1981
Johannesburg Hospital, South Africa, 1981-1982
Internship, General Surgery Resident, Internal Medicine Resident
No. 1 Military Hospital, South Africa, 1983-1984
Medical Officer (Full Lieutenant), Department of internal medicine
Johannesburg Hospital, South Africa 1985-1986
Neurology Resident, Department of Neurology
University of Massachusetts Medical School 1986-1989
Neurology Resident, Department of Neurology
University of Massachusetts Medical School 1989-1990
Neurophysiology Fellow: EEG and EMG Fellowship
LICENSURE
California Medical License Number – A47863
Published Journals
Published Journals
- Blumenfeld AM, Tepper SJ, Robbins LD, et al. Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. J Neurol Neurosurg Psychiatry.
- Blumenfeld NB
- Blumenfeld Cephalagia 2010 Epub
- Burnstein – MOA of Botulinumtoxin A in Migraine – Head 13849
- Brin MF et al. Pregnancy outcomes following exposure to onabotulinumtoxinA. Pharmacoepidemiology and drug safety (2015)
- Glossopharyngeal Neuralgia
- Goadsby et al 2020 Time Course of Efficacy of Ubrogepant
- Head 2058
- Head 2071
- Head 12053
- Head 12053[2]
- Headache Response 2011 [2]
- PREEMPT (Injection Paradigm) E-Published 4-7-17
- Sanderson JNNP 2013 HRU in EM and CM in 6 countries
- SPG Review – Headache 2015
Disclosures
Disclosures
Speaker: Allergan, Abbvie, Amgen, Biohaven, Lundbeck, Lilly, Teva, BDSI
Consultant: Allergan, Abbvie, Alder, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Teva, Theranica
Grant support: Allergan, Amgen
Contributing author: Allergan, Abbvie, Amgen, Novartis, Teva, Lilly, Biohaven